Free Access
Issue
Med Sci (Paris)
Volume 24, Number 12, Décembre 2008
Page(s) 1017 - 1019
Section Nouvelles
DOI https://doi.org/10.1051/medsci/200824121017
Published online 15 December 2008
  1. Simpson JY. Contributions to the pathology and treatment of diseases of the uterus. London and Edinburgh Monthly Journal of Medical Science 1843; 3 : 1008–11. [Google Scholar]
  2. Poiseuille J. Recherches sur la force du coeur aortique. Archives Générales de Médecine 1828; 8 : 550–4. [Google Scholar]
  3. Korotkov N. On methods of studying blood pressure Izvest. Imp. Voyenno-Med. Akad St Petersburgh 1905; 11 : 365. [Google Scholar]
  4. Purkerson ML, Vekerdy L. A history of eclampsia, toxemia and the kidney in pregnancy. Am J Nephrol 1999; 19 : 313–9. [Google Scholar]
  5. Hiby, SE, Walker JJ, O’shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200 : 957–65. [Google Scholar]
  6. Redman, CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308 : 1592–4. [Google Scholar]
  7. Germain SJ, Sacks GP, Sooranna SR, et al. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J Immunol 2007; 178 : 5949–56. [Google Scholar]
  8. Van Dijk M, Poutsma A, Könst AA, et al. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. Nat Genet 2005; 37 : 514–9. [Google Scholar]
  9. Kivinen K, Peterson H, Hiltunen L, et al. Evaluation of STOX1 as a preeclampsia candidate gene in a population-wide sample. Eur J Hum Genet 2007; 15 : 494–7. [Google Scholar]
  10. Berends AL, Bertoli-Avella AM, de Groot CJ, et al. STOX1 gene in pre-eclampsia and intrauterine growth restriction. Br J Obst Gynecol 2007; 114 : 1163–7. [Google Scholar]
  11. Iglesias-Platas I, Monk D, Jebbink J, et al. STOX1 is not imprinted and is not likely to be involved in preeclampsia. Nat Genet 2007; 39 : 279–80. [Google Scholar]
  12. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12 : 642–9. [Google Scholar]
  13. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 : 992–1005. [Google Scholar]
  14. Kanayama N, Takahashi K, Matsuura T, et al. Deficiency in p57Kip2 expression induces preeclampsia-like symptoms in mice. Mol Hum Reprod 2002; 8 : 1129–35. [Google Scholar]
  15. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008; 453 : 1117–21. [Google Scholar]
  16. Chelbi ST, Mondon F, Jammes H, et al. Expressional and epigenetic alterations of placental serine protease inhibitors: SERPINA3 is a potential marker of preeclampsia. Hypertension 2007; 49 : 76–83. [Google Scholar]
  17. Zhou CC, Zhang Y, Irani RA, et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14 : 855–62. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.